Start: May 1, 2019
End: June 2023
What Is This Study About?
Neurodegenerative diseases like Alzheimer's and Parkinson's are characterized by the clumping of specific proteins, but how and if this clumping results in cell death is unknown. The brain responds to this protein clumping with an immune response. This study aims to better understand the role of immune response inflammation in these diseases. Study participants will attend up to two study visits, each involving brief questionnaires and blood draw collections. Tele-visit and mobile phlebotomy visits are also available.
Do I Qualify To Participate in This Study?
- Diagnosis of Parkinson's disease and two of the following three symptoms: rest tremor, rigidity, or bradykinesia, that improves with dopamine medication
- Diagnosis of mild Alzheimer's disease or amnestic mild cognitive impairment, with a Clinical Dementia Rating Scale (CDR) score of 0.5 or 1 and a Mini-Mental State Exam (MMSE) score of 20-26
- No cognitive impairment (Montreal Cognitive Assessment score: 26 and CDR: 0) and no history of Parkinson's disease in first-degree blood relatives (i.e., parents, children, brothers, and sisters)
- Willingness to have genotyping and genetic studies
Must NOT have:
- Symptoms of a Parkinson-plus disorder (e.g., progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration)
- Advanced Alzheimer's disease or other dementia
- Recent history of cancer, in the past three years, except skin cancer
- Autoimmune disease or disease of the immune system (e.g., chronic leukemia, HIV)
- Taking chronic immune-modulatory medication (e.g., oral steroids, azathioprine, rituximab)
- Inability to provide informed consent
If I Qualify, Who Do I Contact?
Contact study personnel listed either under the general study contact or the location nearest you.
Yaqian Xu, MD, MPH
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Where Is This Study Located?
Lead: Columbia University
Source: ClinicalTrials.gov ID: NCT04239079